iCeutica is a privately held pharmaceutical research and development company located in King of Prussia, PA. iCeutica applies our proprietary SoluMatrix™ Fine Particle Technology to both approved and development stage drug compounds, creating new branded medicines independently and in collaboration with selected pharmaceutical partners. The resulting products provide meaningful clinical benefits for patients and have clearly defined pathways to regulatory and commercial success. There are currently four FDA approved and marketed prescription drugs that use SoluMatrix Fine Particle Technology (pain drugs Zorvolex™, Tivorbex™, and Vivlodex™ and prostate cancer drug Yonsa®). In addition, iCeutica and our partners have several pipeline products in various stages of development.